

U.S. Pharmaceuticals

3401 Princeton Pike, Lawrenceville, NJ 08648

June 2, 2020

BY ELECTRONIC DELIVERY

Vermont Attorney General’s Office 109 State Street

Montpelier, VT 05609

AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Bristol-Myers Squibb is providing notice of the introduction of a new prescription drug with a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program.

On June 1, 2020, the following drug products became available for purchase by patients:

* ZEPOSIA® (ozanimod) 7 day titration pack

NDC 59572-810-07

* ZEPOSIA ® (ozanimod) 0.92 mg 30 count bottle

NDC 59572-820-30

* ZEPOSIA ® (ozanimod) starter kit (7 day titration pack + 0.92 mg 30 count bottle)

NDC 59572-890-91

This notice is provided within three calendar days following the release of the drug in the commercial market, as required by 18 V.S.A. § 4637(b). Since 18 V.S.A. § 4637 does not define “release of the drug in the commercial market,” we have based our three-day notice on the date that the products became available for purchase by patients.

In the event Vermont S. 92 and the laws it implements, including 18 V.S.A. § 4637, are found invalid, Bristol-Myers Squibb reserves all of its legal rights. In issuing this notice in an attempt to comply with 18 V.S.A. § 4637, Bristol-Myers Squibb does not waive any legal claims or legal rights related to constitutional or other defects arising under Vermont S. 92.

Sincerely,

Kinneret Klein

Senior Manager, State Price Transparency